T Anderson

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky et al. · The Lancet · 2015 · 1.2K citations

Nanomedicine, Oncology, Pancreatic Cancer +8

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.

T Anderson, RA Bender, Fisher Ri et al. · PubMed · 1977 · 113 citations

Lymphoid Neoplasia, Combination Chemotherapy, Medicine +4

Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling

Frankie A. Holmes, Virginia Espina, Lance A. Liotta et al. · BMC Research Notes · 2013 · 74 citations · Full text

Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.

F. A. Holmes, Yasir M. Nagarwala, Virginia Espina et al. · Journal of Clinical Oncology · 2011 · 48 citations